Research programme: cancer therapeutics - Taiho Pharmaceutical

Drug Profile

Research programme: cancer therapeutics - Taiho Pharmaceutical

Alternative Names: TAS-117; TAS-2913; TAS-2985; TAS-4464; TAS-5567; TPC-064; TPC-107

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor antagonists; HSP90 heat-shock protein inhibitors; NEDD 8 activating enzyme inhibitors; Proto oncogene protein c-akt inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma; Cancer; Non-small cell lung cancer; Soft tissue sarcoma
  • Phase Unknown Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Jan 2017 Taiho Pharmaceutical plans a phase IA/IB trial in Cancer in Japan (JapicCTI173488)
  • 29 Nov 2016 Preclinical trials in Non-small cell lung cancer in Japan (PO) before November 2016
  • 29 Nov 2016 Pharmacodynamics data from preclinical studies in Cancer presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016) (3214873; 3214875)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top